CALL/EVOTEC/35/0.1/20.06.25 Stock

Warrant

DE000GP97YF5

Real-time BOERSE MUENCHEN 12:25:07 2024-07-16 pm EDT
0.022 EUR -4.35% Intraday chart for CALL/EVOTEC/35/0.1/20.06.25
Current month-28.12%
1 month-34.29%
Date Price Change
24-07-16 0.022 -4.35%
24-07-15 0.023 -4.17%
24-07-12 0.024 0.00%
24-07-11 0.024 -11.11%
24-07-10 0.027 -10.00%

Real-time BOERSE MUENCHEN

Last update July 16, 2024 at 12:25 pm EDT

More quotes

Static data

Product typeWarrant Plain-Vanilla
Buy / SellCALL
Underlying EVOTEC SE
Issuer Goldman Sachs
WKN GP97YF
ISINDE000GP97YF5
Date issued 2023-07-19
Strike 35
Maturity 2025-06-20 (339 Days)
Parity 10 : 1
Emission price 0.15
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.297
Lowest since issue 0.022
Spread 0.01
Spread %31.25%

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
8.87 EUR
Average target price
20.72 EUR
Spread / Average Target
+133.58%
Consensus